Healthcare / Drug Manufacturers - Specialty & GenericKSE
$19550.00
+10.00 (+0.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $9.6B · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$239.6B
P/E
10.0x
↓EV/EBITDA
7.8x
↓ROE
8.3%
↑Gross Margin
40.5%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.1%
FCF CAGR
—
FCF margin
3.1%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $309.13B · net income $24.17B · FCF $9.62B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $309.13B | $309.13B | $308.35B | $292.13B | $274.03B |
| Net Income | $24.17B | $24.17B | $39.23B | $18.91B | $21.89B |
| EBITDA | $46.87B | $46.87B | $65.92B | $36.60B | $36.81B |
| EPS | 1963.00 | 1963.00 | 3111.00 | 1460.00 | 1728.00 |
| Gross Margin | 40.5% | 40.5% | 41.8% | 39.9% | 43.0% |
| Operating Margin | 8.7% | 8.7% | 10.3% | 7.0% | 8.5% |
| Net Margin | 7.8% | 7.8% | 12.7% | 6.5% | 8.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.46 | 0.45 | 0.32 |
| Current Ratio | 4.29 | 4.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9.62B | $9.62B | $19.81B | $-12.39B | $-18.20B |
| Returns | |||||
| ROE | 8.3% | 8.3% | 15.0% | 7.1% | 8.0% |
| Valuation | |||||
| P/E | 9.96 | 9.96 | 5.77 | 14.35 | 14.32 |
| EV/EBITDA | 7.77 | 7.77 | 5.22 | 10.59 | 10.83 |
| P/B | 0.83 | 0.83 | 0.86 | 1.02 | 1.14 |
| Growth & Yield | |||||
| Revenue Growth | 0.3% | 0.3% | 5.6% | 6.6% | — |
| EPS Growth | -36.9% | -36.9% | 113.1% | -15.5% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-4.0%
EPS terminal req.
$1734.74
Spread vs growth
-32.9%
5Y implied EPS CAGR
1.3%
EPS terminal req.
$2099.03
Spread vs growth
-38.3%
10Y implied EPS CAGR
5.6%
EPS terminal req.
$3380.51
Spread vs growth
-42.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.9%
Start / end P/E
5.6x → 10.0x
EPS bridge
3111.00 → 1963.00
Residual
-29.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.